Randomized, double-blind, placebo-controlled add-on trial of the safety and efficacy of RO4917838 [R 1678] in outpatients on select atypical antipsychotics with prominent negative or disorganized thought symptoms.

Trial Profile

Randomized, double-blind, placebo-controlled add-on trial of the safety and efficacy of RO4917838 [R 1678] in outpatients on select atypical antipsychotics with prominent negative or disorganized thought symptoms.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 May 2016

At a glance

  • Drugs Bitopertin (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 02 Apr 2014 Results published in the JAMA Psychiatry.
    • 07 Sep 2011 Results presented at the 24th Annual Congress of the European College of Neuropsychopharmacology.
    • 07 Dec 2010 Results were reported in a Genentech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top